Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.

Oncogene·2015
Same author

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors.

British journal of cancer·2010
Same author

Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.

Anticancer research·2009
Same author

Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.

American journal of hematology·2005
Same author

Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.

Bone marrow transplantation·2003
Same author

Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.

Leukemia·2002

相关实验视频

Updated: Jun 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

红细胞谷氨和瘤对化疗的反应

A Hercbergs1, F Brok-Simoni, F Holtzman

  • 1Department of Radiation Therapy, Cleveland Clinic Foundation, Ohio 44195-5213.

Lancet (London, England)
|May 2, 1992
PubMed
概括
此摘要是机器生成的。

瘤谷氨 (GSH) 度会影响化疗耐药性. 测量血液中的红细胞GSH可以预测患者对癌症治疗的反应,避免侵入性瘤采样.

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关实验视频

Last Updated: Jun 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

科学领域:

  • 在瘤学瘤学.
  • 生物化学 生物化学
  • 临床医学 临床医学

背景情况:

  • 瘤谷氨 (GSH) 水平与化疗耐药性有关.
  • 直接测量瘤GSH是侵入性的,对于例行患者护理是不切实际的.

研究的目的:

  • 调查红细胞GSH度与癌症患者化疗反应之间的相关性.
  • 确定外周血液GSH水平是否可以作为瘤GSH的替代标记物,并预测治疗结果.

主要方法:

  • 谱光测量用于测量周围血液样本中的红细胞GSH度.
  • 患者包括那些患有晚期乳腺癌和接受常规化疗的其他瘤类型的患者.
  • 在治疗前和治疗后进行测量,以评估变化和相关性.

主要成果:

  • 在获得化学疗法的完全或部分反应的患者中观察到较低的治疗前红细胞GSH度.
  • 这一发现在晚期乳腺癌队列和其他瘤队列中是一致的.
  • 在响应者和非响应者之间发现了平均GSH水平的统计学上显著差异 (p < 0.01).

结论:

  • 红细胞GSH度与化疗反应率相关.
  • 测量红细胞GSH可能提供一种非侵入性方法来预测患者对癌症治疗的反应.
  • 这种方法可以帮助为癌症患者制定个性化治疗策略.